Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases

References

• Nurmohamed MT, Heslinga M, Kitas GD. Cardiovascular comorbidity in rheumatic diseases. Nat Rev Rheumatol. 2015;11(12):693–704.
   PubMed Web of Science ®Google Scholar
• Stamatelopoulos KS, Kitas GD, Papamichael CM, et al. Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study. Arterioscler Thromb Vasc Biol. 2009;29(10):1702–1708.
   PubMed Web of Science ®Google Scholar
• Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17–28.
   PubMed Web of Science ®Google Scholar
• Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: an update. Curr Opin Rheumatol. 2018;30(5):441–448.
   PubMed Web of Science ®Google Scholar
• Nikiphorou E, de Lusignan S, Mallen CD, et al. Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. Heart. 2020. 10.1136/heartjnl-2019-316193.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Liakouli V, et al. Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Arthritis Res Ther. 2019;21(1):204.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Margiotta DPE, Macaluso F, et al., Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Medicine (Baltimore). 96(42): e8180. 2017. .
   PubMed Web of Science ®Google Scholar
• Charlton R, Green A, Shaddick G, et al. Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. Rheumatology (Oxford). 2019;58(1):144–148.
   PubMed Web of Science ®Google Scholar
• Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum. 2011;63(11):3294–3304.
   PubMed Web of Science ®Google Scholar
• Man A, Zhu Y, Zhang Y, et al. The risk of cardiovascular disease in systemic sclerosis: a population-based cohort study. Ann Rheum Dis. 2013;72(7):1188–1193.
   PubMed Web of Science ®Google Scholar
• Berardicurti O, Ruscitti P, Cipriani P, et al. Cardiovascular disease in primary sjogren’s syndrome. Rev Recent Clin Trials. 2018;13(3):164–169.
   PubMed Web of Science ®Google Scholar
• Sandoo A, van Zanten JJ, Metsios GS, et al. The endothelium and its role in regulating vascular tone. Open Cardiovasc Med J. 2010;4(1):302–312.
   PubMedGoogle Scholar
• Conroy RM, Pyorala K, Fitzgerald AP, et al., Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 24(11): 987–1003. 2003.
   PubMed Web of Science ®Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
   PubMed Web of Science ®Google Scholar
• Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331.
   PubMed Web of Science ®Google Scholar
• Crowson CS, Rollefstad S, Ikdahl E, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48–54.
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.
   PubMed Web of Science ®Google Scholar
• Innala L, Moller B, Ljung L, et al. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther. 2011;13(4):R131.
   PubMed Web of Science ®Google Scholar
• Arts EE, Fransen J, den Broeder AA, et al. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis. 2015;74(6):998–1003.
   PubMed Web of Science ®Google Scholar
• Arts EE, Fransen J, Den Broeder AA, et al. Low disease activity (DAS28. Ann Rheum Dis. 2017;76(10):1693–1699.
   PubMed Web of Science ®Google Scholar
• Provan SA, Semb AG, Hisdal J, et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis. 2011;70(5):812–817.
   PubMed Web of Science ®Google Scholar
• Metsios GS, Kitas GD. Physical activity, exercise and rheumatoid arthritis: effectiveness, mechanisms and implementation. Best Pract Res Clin Rheumatol. 2018;32(5):669–682.
   PubMed Web of Science ®Google Scholar
• Burggraaf B, van Breukelen-van der Stoep DF, MA DV, et al. Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2019;78(3):335–341.
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Ayvazyan L, Blackmore H, et al. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011;31(11):1409–1417.
   PubMed Web of Science ®Google Scholar
• TE T, Symmons DP, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharmacol. 2010;8(3):301–326.
   PubMed Web of Science ®Google Scholar
• Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis–the Third national health and nutrition examination survey. J Rheumatol. 2005;32(12):2311–2316.
   PubMed Web of Science ®Google Scholar
• van Halm VP, Nielen MM, Nurmohamed MT, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):184–188.
   PubMed Web of Science ®Google Scholar
• Giles JT, Wasko MCM, Chung CP, et al. Exploring the lipid paradox theory in rheumatoid arthritis: associations of low circulating low-density lipoprotein concentration with subclinical coronary atherosclerosis. Arthritis Rheumatol. 2019;71(9):1426–1436.
   PubMed Web of Science ®Google Scholar
• Romano S, Salustri E, Ruscitti P, et al. Cardiovascular and metabolic comorbidities in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(12):81.
   PubMed Web of Science ®Google Scholar
• Nuttall SL, Heaton S, Piper MK, et al. Cardiovascular risk in systemic lupus erythematosus–evidence of increased oxidative stress and dyslipidaemia. Rheumatology (Oxford). 2003;42(6):758–762.
   PubMed Web of Science ®Google Scholar
• Szabo MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017;65(2):543–550.
   PubMed Web of Science ®Google Scholar
• Suciu CF, Prete M, Ruscitti P, et al. Oxidized low density lipoproteins: the bridge between atherosclerosis and autoimmunity. Possible implications in accelerated atherosclerosis and for immune intervention in autoimmune rheumatic disorders. Autoimmun Rev. 2018;17(4):366–375.
   PubMed Web of Science ®Google Scholar
• Nurmohamed MT, Dijkmans BAC. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis. 2009;68(4):453–455.
   PubMed Web of Science ®Google Scholar
• Medina G, Casaos D, Jara L, et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis. 2003;62(7):607–610.
   PubMed Web of Science ®Google Scholar
• Vlachoyiannopoulos PG. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology (Oxford). 2003;42(5):645–651.
   PubMed Web of Science ®Google Scholar
• Gerli R, Bartoloni Bocci E, Vaudo G, et al. Traditional cardiovascular risk factors in primary Sjogren’s syndrome–role of dyslipidaemia. Rheumatology (Oxford). 2006;45(12):1580–1581. author reply 1581-2.
   PubMed Web of Science ®Google Scholar
• Lodde BM, Sankar V, Kok MR, et al. Serum lipid levels in Sjogren’s syndrome. Rheumatology (Oxford). 2006;45(4):481–484.
   PubMed Web of Science ®Google Scholar
• Hettema ME, Bootsma H, Kallenberg CG. Macrovascular disease and atherosclerosis in SSc. Rheumatology (Oxford). 2008;47(5):578–583.
   PubMed Web of Science ®Google Scholar
• Kodera M, Hayakawa I, Komura K, et al. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations. J Rheumatol. 2005;32(4):629–636.
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188.
   PubMed Web of Science ®Google Scholar
• Musa-Veloso K, Poon TH, Elliot JA, et al. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2011;85(1):9–28.
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485–494.
   PubMed Web of Science ®Google Scholar
• Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265(5):568–580.
   PubMed Web of Science ®Google Scholar
• Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis. 2012;223(2):251–261.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Abifadel M, Varret M, Rabes J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–156.
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–1499.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al., Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 376(18): 1713–1722. 2017.
   PubMed Web of Science ®Google Scholar
• Nozue T. Lipid Lowering Therapy and Circulating PCSK9 Concentration. J Atheroscler Thromb. 2017;24(9):895–907.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Sabatine MS, Ott BR. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377:1997.
   PubMed Web of Science ®Google Scholar
• Ferraz-Amaro I, Lopez-Mejias R, Ubilla B, et al. Proprotein convertase subtilisin/kexin type 9 in rheumatoid arthritis. Clin Exp Rheumatol. 2016;34(6):1013–1019.
   PubMed Web of Science ®Google Scholar
• Ferraz-Amaro I, Hernandez-Hernandez MV, Tejera-Segura B, et al. Effect of IL-6 receptor blockade on proprotein convertase subtilisin/kexin type-9 and cholesterol efflux capacity in rheumatoid arthritis patients. Horm Metab Res. 2019;51(3):200–209.
   PubMed Web of Science ®Google Scholar
• Kitas GD, Nightingale P, Armitage J, et al., A multicenter, randomized, placebo-controlled trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheumatol. 71(9): 1437–1449. 2019.
   PubMed Web of Science ®Google Scholar
• Fulcher J, O’Connell R, Voycey M. et al.; Cholesterol Treatment Trialists C. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405.
   PubMed Web of Science ®Google Scholar
• Panoulas VF, Douglas KM, Milionis HJ, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology (Oxford). 2007;46(9):1477–1482.
   PubMed Web of Science ®Google Scholar
• Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(9):1286–1298.
   PubMed Web of Science ®Google Scholar
• Munguia-Realpozo P, Mendoza-Pinto C, Sierra Benito C, et al. Systemic lupus erythematosus and hypertension. Autoimmun Rev. 2019;18(10):102371.
   PubMed Web of Science ®Google Scholar
• Taylor EB, Wolf VL, Dent E, et al. Mechanisms of hypertension in autoimmune rheumatic diseases. Br J Pharmacol. 2019;176(12):1897–1913.
   PubMed Web of Science ®Google Scholar
• Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al., Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford). 47(1): 72–75. 2008.
   PubMed Web of Science ®Google Scholar
• Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis. 2002;61(6):567–569.
   PubMed Web of Science ®Google Scholar
• Porter GA, Bennett WM, Sheps SG. Cyclosporine-associated hypertension. National high blood pressure education program. Arch Intern Med. 1990;150(2):280–283.
   PubMedGoogle Scholar
• Sandoo A, Panoulas VF, Toms TE, et al. Anti-TNFalpha therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis. J Hum Hypertens. 2011;25(11):699–702.
   PubMed Web of Science ®Google Scholar
• Ursini F, Ruscitti P, Caio GPI, et al. The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A systematic literature review. Autoimmun Rev. 2019;18(5):501–509.
   PubMed Web of Science ®Google Scholar
• Gulick T, Chung MK, Pieper SJ, et al. Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc Natl Acad Sci U S A. 1989;86(17):6753–6757.
   PubMed Web of Science ®Google Scholar
• Daneshtalab N, Lewanczuk RZ, Russell A, et al. Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan. J Clin Pharmacol. 2004;44(3):245–252.
   PubMed Web of Science ®Google Scholar
• Daneshtalab N, Lewanczuk RZ, Russell AS, et al. Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis. J Clin Pharmacol. 2006;46(11):1344–1355.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Kardiol Pol. 2019;77:71–159.
   PubMed Web of Science ®Google Scholar
• Parati G, Stergiou G, O’Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359–1366.
   PubMed Web of Science ®Google Scholar
• Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res. 2015;116(6):1034–1045.
   PubMed Web of Science ®Google Scholar
• Domenech M, Roman P, Lapetra J, et al. Mediterranean diet reduces 24-hour ambulatory blood pressure, blood glucose, and lipids: one-year randomized, clinical trial. Hypertension. 2014;64(1):69–76.
   PubMed Web of Science ®Google Scholar
• Stavropoulos-Kalinoglou A, Metsios GS, Veldhuijzen van Zanten JJ, et al. Individualised aerobic and resistance exercise training improves cardiorespiratory fitness and reduces cardiovascular risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72(11):1819–1825.
   PubMed Web of Science ®Google Scholar
• Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, et al. Individualised exercise improves endothelial function in patients with rheumatoid arthritis. Ann Rheum Dis. 2014;73(4):748–751.
   PubMed Web of Science ®Google Scholar
• Metsios GS, Moe RH, van der Esch M, et al. The effects of exercise on cardiovascular disease risk factors and cardiovascular physiology in rheumatoid arthritis. Rheumatol Int. 2020 Mar 40(3):347-357.
   PubMed Web of Science ®Google Scholar
• Williams B, MacDonald TM, Morant SV, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6(6):464–475.
   PubMed Web of Science ®Google Scholar
• Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–2222.
   PubMed Web of Science ®Google Scholar
• Chung CP, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. Arthritis Rheum. 2008;58(7):2105–2112.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Love TJ, Canning C, et al. Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis. 2010;69(12):2114–2117.
   PubMed Web of Science ®Google Scholar
• Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto risk factor study. Arthritis Rheum. 2003;48(11):3159–3167.
   PubMed Web of Science ®Google Scholar
• Lillegraven S, Greenberg JD, Reed GW, et al. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One. 2019;14(1):e0210459.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ursini F, Cipriani P, et al. Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. PLoS One. 2017;12(7):e0181203.
   PubMed Web of Science ®Google Scholar
• van Sijl AM, Boers M, AE V, et al. Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study. PLoS One. 2014;9(1):e87965.
   PubMed Web of Science ®Google Scholar
• Chen YM, Lin CH, Lan TH, et al. Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology (Oxford). 2015;54(7):1244–1249.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ursini F, Cipriani P, et al. IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: an observational study. Medicine (Baltimore). 2019;98(7):e14587.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Masedu F, Alvaro S, et al., Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Med. 16(9): e1002901. 2019.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Ruscitti P, Alvaro S, et al. IL-1beta at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? Expert Rev Clin Immunol. 2016;12(8):849–855.
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255–323.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39.
   PubMed Web of Science ®Google Scholar
• Semb AG, Ikdahl E, Hisdal J, et al. Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases. Int J Cardiol. 2016;223:331–336.
   PubMed Web of Science ®Google Scholar
• Prasad M, Hermann J, Gabriel SE, et al. Cardiorheumatology: cardiac involvement in systemic rheumatic disease. Nat Rev Cardiol. 2015;12(3):168–176.
   PubMed Web of Science ®Google Scholar